29 research outputs found
Increased Expression of Musashi-1 Evidences Mesenchymal Repair in Maxillary Sinus Floor Elevation
This study aimed to analyze the expression of Musashi-1 (MSI1) in maxillary native bone and grafted
bone after maxillary sinus floor elevation. To do so, fifty-seven bone biopsies from 45 participants were
studied. Eighteen samples were collected from native bone while 39 were obtained 6 months after
maxillary sinus grafting procedures. Musashi-1 was analyzed by immunohistochemistry and RT-PCR.
MSI1 was detected in osteoblasts and osteocytes in 97.4% (38/39) of grafted areas. In native bone,
MSI1 was detected in only 66.6% (12/18) of the biopsies, mainly in osteocytes. Detection of MSI1 was
significantly higher in osteoprogenitor mesenchymal cells of grafted biopsies (p < 0.001) but minor in
smooth muscle and endothelial cells; no expression was detected in adipocytes. The mesenchymal cells
of the non-mineralized tissue of native bone showed very low nuclear expression of MSI1, in comparison
to fusiform cells in grafted areas (0.28(0.13) vs. 2.10(0.14), respectively; p < 0.001). Additionally, the
detection of MSI1 mRNA was significantly higher in biopsies from grafted areas than those from native
bone (1.00(0.51) vs. 60.34(35.2), respectively; p = 0.029). Thus, our results regardig the significantly
higher detection of Musashi-1 in grafted sites than in native bone reflects its importance in the
remodeling/repair events that occur after maxillary sinus floor elevation in humans.This investigation was partially supported by Research Groups #CTS-138
and #CTS-1028 (Junta de AndalucĂa, Spain). MPM was supported by the AndalucĂa Talent Hub Program from
the Andalusian Knowledge Agency (co-funded by the European Unionâs Seventh Framework Program, Marie
SkĆodowska-Curie actions (COFUND â Grant Agreement n° 291780) and the Ministry of Economy, Innovation,
Science and Employment of the Junta de AndalucĂa)
The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy
Background: Despite much effort on the treatment of breast cancer over the decades, a great uncertainty regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists. This research was performed to analyze the association of SPAG5 gene expression with clinicopathological factors and survival outcomes. Methods: We used a breast cancer database including 5667 patients with a mean follow-up of 69 months. Kaplan-Meier survival analyses for relapse free survival (RFS), overall survival (OS), and distant metastasis-free survival (DMFS) were performed. In addition, ROC analysis was performed to validate SPAG5 as a prognostic candidate gene. Results: Mean SPAG5 expression value was significantly higher with some clinicopathological factors that resulted in tumor promotion and progression, including poor differentiated type, HER2 positive or TP53 mutated breast cancer. Based on ROC-analysis SPAG 5 is a suitable prognostic marker of poor survival. In patients who received chemotherapy alone, SPAG5 had only a moderate and not significant predictive impact on survival outcomes. However, in hormonal therapy, high SPAG5 expression could strongly predict prognosis with detrimental RFS (HR = 1.57, 95% CI 1.2-2.06, p = 0.001), OS (HR = 2, 95% CI 1.05-3.8, p = 0.03) and DMFS (HR = 2.36, 95% CI 1.57-3.54, p < 0.001), respectively. In addition, SPAG5 could only serve as a survival predictor in ER+, but not ER- breast cancer patients. Patients might also be at an increased risk of relapse despite being diagnosed with a lower grade cancer (well differentiated type). Conclusions: SPAG5 could be used as an independent prognostic and predictive biomarker that might have clinical utility, especially in ER+ breast cancer patients who received hormonal therapy. © 2019 The Author(s)